Faron Publishes Research From INTEREST Trial
Faron Pharmaceuticals Ltd (“Faron” or “Company”) Faron Publishes Research Identifying Gene Mutation in Interferon Receptor that Contributes to Corticosteroid Response and Outcome in ARDS and COVID-19 Patients · Single nucleotide polymorphism identified during analysis of data from Phase III INTEREST trial of Traumakine · Gene mutation in interferon alpha/beta receptor (IFNAR2) is associated with better outcomes among intravenous interferon beta-1a treated ARDS patients, irrespective of prior treatment with glucocorticosteroids · Analysis of COVID-19 Host